| P50 | author | Sergio Giralt | Q66764444 |
| P2093 | author name string | Mary Horowitz | |
| | Corey Cutler | |
| | Daniel Weisdorf | |
| P2860 | cites work | Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study | Q24563021 |
| | The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997 | Q28142473 |
| | Proposals for the classification of the myelodysplastic syndromes | Q28275931 |
| | Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study | Q28301602 |
| | International scoring system for evaluating prognosis in myelodysplastic syndromes | Q28305247 |
| | Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion | Q33372867 |
| | Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System | Q33380307 |
| | Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia | Q33706393 |
| | Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome | Q33813439 |
| | Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. | Q34128471 |
| | A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome | Q34308142 |
| | Nonablative stem cell transplantation for older patients with acute leukemias and myelodysplastic syndromes | Q34499747 |
| | Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. | Q34577019 |
| | Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome | Q34924442 |
| | Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation | Q35828727 |
| | Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders | Q36484688 |
| | Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome | Q36915178 |
| | Cause of death in patients with lower-risk myelodysplastic syndrome | Q37120849 |
| | The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review | Q37376862 |
| | Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS) | Q37380958 |
| | Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries | Q37737483 |
| | Current therapeutic approaches for patients with myelodysplastic syndromes | Q37761183 |
| | Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia | Q40945830 |
| | Genotypically nonidentical related donors for transplantation of patients with myelodysplastic syndromes: comparison with unrelated donor transplantation and autologous stem cell transplantation | Q43593866 |
| | Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study | Q43951562 |
| | Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome | Q44083618 |
| | A prognostic score for patients with lower risk myelodysplastic syndrome | Q44103626 |
| | Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors | Q44117841 |
| | Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes | Q44175621 |
| | The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK a | Q44443448 |
| | Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia | Q44548405 |
| | Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. | Q44836524 |
| | Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome | Q45206583 |
| | 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. | Q45960014 |
| | Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation | Q46046970 |
| | Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. | Q46722601 |
| | Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. | Q50861956 |
| | Increasing incidence of myelodysplastic syndromes: real or fictitious? | Q52902521 |
| | Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. | Q53339364 |
| | Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. | Q53532028 |
| | Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. | Q53628688 |
| | Myelodysplastic syndromes | Q56906508 |
| | Performance Status and Comorbidity Predict Transplant-Related Mortality After Allogeneic Hematopoietic Cell Transplantation | Q59315420 |
| | Graft-versus-host disease | Q68195420 |
| | Treatment of preleukemic syndromes with marrow transplantation | Q68921894 |
| | Allogeneic Marrow Transplantation in the Treatment of Preleukemia | Q70337005 |
| | Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Société Française de Greffe de Moelle | Q71249405 |
| | Leukemia relapse after allogeneic bone marrow transplantation: a review | Q72776679 |
| | Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy | Q73436821 |
| | Myelodysplasia | Q73476620 |
| | Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases | Q74106097 |
| | Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy) | Q74136753 |
| | Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) | Q74346540 |
| | Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation | Q77436747 |
| | Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program | Q77725427 |
| | Predicting survival and leukemic evolution in patients with myelodysplastic syndrome | Q79404786 |
| | Myelodysplastic syndromes: incidence and survival in the United States | Q79899691 |
| | Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation | Q79945430 |
| | Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes | Q80768443 |
| | New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients | Q80860421 |
| | WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) | Q81322446 |
| | Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome | Q81326649 |
| | Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia | Q82236404 |
| | Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome | Q83833940 |
| | Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival | Q84233130 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | myelodysplastic syndrome | Q954625 |
| | stem cell transplantation | Q65592366 |
| P304 | page(s) | 566-572 | |
| P577 | publication date | 2011-01-10 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and M | |
| P478 | volume | 29 | |